

Trifluridine/Tipiracil (TAS-102) SUNLIGHT

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



QoL data pending



Serious and disabling adverse effects



Other adjustments



Trifluridine/Tipiracil (TAS-102) SUNLIGHT

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment of patients with mCRC who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based ChT, anti-VEGF agents and/or anti-EGFR agents

Experimental Arm: Trifluridine/Tipiracil (TAS-102) + Bevacizumab

Control Arm: Trifluridine/Tipiracil (TAS-102)



